Interleukin-12 Archives

Plaque Psoriasis Drug Outperforms Competition in Phase III Trial

Blockbusters, Bristol Myers Squibb, Clinical Trial Endpoints, Clinical Trials, Interleukin-12, Placebo, Plaque Psoriasis, Primary Endpoints, R&D, Secondary Endpoints, Therapeutics, Tyk2 (tyrosine kinase 2) Antagonists

Bristol Myers Squibb announced positive data from POETYK PSO-2, the second Phase III trial of deucravacitinib for moderate to severe plaque psoriasis, evaluated against placebo and Amgen’s Otezla (apremilast).

February 2, 2021/by Andrew Humphreys

Bristol Myers Squibb Licenses IL-12 from Dragonfly

Business, Cancer, Clinical Data, Clinical Trials, Collaborations, Hematologic malignancies, Hematology, Immunoglobulin G (IgG), Immunotherapies, Interleukin-12, Licensing, Oncology, PD-1/PD-L1 inhibitors, R&D, Solid Tumors

Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program, including the extended half-life cytokine DF6002 as a potential treatment for solid and hematological cancers.

August 17, 2020/by Andrew Humphreys